It’s been a banner year for the pot industry.
New public sentiment on pot, medical breakthroughs, legalization, and huge fortunes…
The list could goes on and on with ways pot has stolen the headlines.
The future of pot in the U.S. and abroad, as a commoditized and regulated industry, is looking very bright.
And very lucrative.
It’s almost easy to forget that not long ago cannabis was a vilified substance.
But, in an incredibly short amount of time marijuana has rebranded itself completely.
Instead of stoney hippies, when you think of the pot industry today, the images of high quality laboratories, politicians, and venture capitalists come to mind.
It's one of the most successful rebrandings of a product ever seen.
Now that marijuana has completely revamped its image the big bucks are flowing.
Today we look at some of the most recent marijuana news set to move the needle in 2018.
Huge Loophole Opportunity in CaliforniaA recently discovered loophole in California's marijuana laws means non-residents could open and conduct business in the state.
Top 5 Medical Stocks To Invest In Right Now: Ballard Power Systems, Inc.(BLDP)
Advisors' Opinion:- [By Shane Hupp]
Get a free copy of the Zacks research report on Ballard Power Systems (BLDP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By John Bromels]
Once upon a time -- like, 10 years ago -- hydrogen fuel cells were seen as a leading contender for mass-producing green energy vehicles. Companies like Plug Power and Ballard Power Systems (NASDAQ:BLDP) have turned that potential into reality -- kind of.
- [By Motley Fool Transcription]
Ballard Power Systems Inc. (NASDAQ:BLDP) Q4 and Full Year 2018 Earnings Conference Call March. 07, 2019, 8:00 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Travis Hoium]
Shares of Ballard Power Systems Inc (NASDAQ:BLDP) jumped as much as 11.9% in trading Tuesday after the company announced the sale of some noncore assets. At 12:40 p.m. EDT, shares were still up 9.1% on the day.
Top 5 Medical Stocks To Invest In Right Now: Qualstar Corporation(QBAK)
Advisors' Opinion:- [By Max Byerly]
Qualstar (NASDAQ:QBAK) issued its quarterly earnings data on Wednesday. The electronics maker reported $0.23 earnings per share for the quarter, Bloomberg Earnings reports. Qualstar had a net margin of 10.52% and a return on equity of 20.76%. The business had revenue of $3.23 million during the quarter.
- [By Ethan Ryder]
Media headlines about Qualstar (NASDAQ:QBAK) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Qualstar earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news headlines about the electronics maker an impact score of 45.8526636437463 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Top 5 Medical Stocks To Invest In Right Now: Carpenter Technology Corporation(CRS)
Advisors' Opinion:- [By Max Byerly]
Crystal Amber Fund Limited (LON:CRS) announced a dividend on Friday, July 6th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, July 19th will be given a dividend of GBX 2.50 ($0.03) per share on Friday, August 17th. This represents a yield of 1.12%. The ex-dividend date is Thursday, July 19th. The official announcement can be viewed at this link.
- [By Ethan Ryder]
Titan International (NYSE: TWI) and Carpenter Technology (NYSE:CRS) are both industrial products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.
- [By Logan Wallace]
Carpenter Technology Co. (NYSE:CRS) VP Timothy Lain sold 1,007 shares of the firm’s stock in a transaction that occurred on Friday, May 4th. The stock was sold at an average price of $55.00, for a total transaction of $55,385.00. Following the completion of the transaction, the vice president now directly owns 11,288 shares of the company’s stock, valued at $620,840. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
- [By Max Byerly]
Get a free copy of the Zacks research report on Carpenter Technology (CRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 5 Medical Stocks To Invest In Right Now: Maximus, Inc.(MMS)
Advisors' Opinion:- [By Stephan Byrd]
Get a free copy of the Zacks research report on Maximus (MMS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Violich Capital Management Inc. purchased a new stake in MAXIMUS, Inc. (NYSE:MMS) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,280 shares of the health services provider’s stock, valued at approximately $204,000.
- [By Stephan Byrd]
Shares of MAXIMUS, Inc. (NYSE:MMS) have received an average recommendation of “Hold” from the six ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and three have issued a hold recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $71.33.
Top 5 Medical Stocks To Invest In Right Now: MDC Partners Inc.(MDCA)
Advisors' Opinion:- [By Lisa Levin]
Check out these big penny stock gainers and losers
Losers MDC Partners Inc. (NASDAQ: MDCA) fell 23.4 percent to $5.25 in pre-market trading after a first-quarter earnings miss. Hudson Technologies Inc. (NASDAQ: HDSN) shares fell 15.1 percent to $3.48 in pre-market trading after the company reported downbeat Q1 earnings. Nuance Communications, Inc. (NASDAQ: NUAN) fell 14 percent to $13.15 in pre-market trading after the company posted downbeat Q2 earnings and lowered FY18 organic growth guidance. Myomo, Inc. (NYSE: MYO) fell 13.2 percent to $3.10 in pre-market trading after reporting downbeat quarterly results. Rowan Companies plc (NYSE: RDC) shares fell 10.7 percent to $14.13 in pre-market trading after climbing 8.50 percent on Wednesday. BT Group plc (NYSE: BT) fell 9 percent to $14.80 in pre-market trading after the company reported Q4 results and announced plans to cut 13,000 jobs over the next three years. Exelixis, Inc. (NASDAQ: EXEL) fell 8.3 percent to $19.90 in pre-market trading after the company disclosed that IMblaze370 Phase 3 pivotal trial of atezolizumab and cobimetinib in patients with heavily pretreated locally advanced or metastatic colorectal cancer did not meet primary endpoint. Infinera Corporation (NASDAQ: INFN) fell 8.2 percent to $10.80 in pre-market trading after reporting Q1 results. Synaptics, Incorporated (NASDAQ: SYNA) shares fell 7.4 percent to $43.00 in pre-market trading. Synaptics reported better-than-expected earnings for its third quarter, while sales missed estimates. Randgold Resources Limited (NASDAQ: GOLD) shares fell 7.4 percent to $76.23 in pre-market trading after reporting Q1 earnings. Integra LifeSciences Holdings Corporation (NASDAQ: IART) shares fell 7 percent to $59.36 in pre-market trading. Integra LifeSciences priced its 5.25 million share public offering of common stock at $58.50 per share. Array BioPharma Inc. (NASDAQ: ARRY) shares fell 6.9 percent to $12.75 in pre-m - [By Ethan Ryder]
Here are some of the news stories that may have effected Accern’s analysis:
Get MDC Partners alerts: $0.09 Earnings Per Share Expected for MDC Partners Inc (MDCA) This Quarter (americanbankingnews.com) Head-To-Head Review: MDC Partners (MDCA) vs. HAVAS (HAVSF) (americanbankingnews.com) Telaria (TLRA) & MDC Partners (MDCA) Head to Head Survey (americanbankingnews.com) Comparing WPP (WPP) & MDC Partners (MDCA) (americanbankingnews.com)Shares of MDC Partners traded up $0.15, reaching $4.80, during midday trading on Monday, according to Marketbeat.com. 391,100 shares of the company were exchanged, compared to its average volume of 478,690. The stock has a market cap of $278.13 million, a PE ratio of 7.87, a P/E/G ratio of 1.99 and a beta of 1.13. MDC Partners has a 1-year low of $3.80 and a 1-year high of $12.26. The company has a debt-to-equity ratio of -3.37, a current ratio of 0.74 and a quick ratio of 0.74.
- [By Shane Hupp]
Get a free copy of the Zacks research report on MDC Partners (MDCA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Evan Niu, CFA]
Shares of MDC Partners (NASDAQ:MDCA) have gotten crushed today, down by a whopping 36% as of 11:45 a.m. EDT, after the company reported first-quarter earnings results and lowered its outlook for organic revenue growth this year.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on MDC Partners (MDCA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By ]
In particular, Birchenough notes that he has increased confidence in the results due for Aeglea's lead product candidate pegzilarginase- an enzyme replacement therapy for the treatment of Arginase deficiency and solid tumors.
MDC Partners (MDCA) Current share price: $7.55Keep a close eye on MDC Partners- a fast-growing marketing and communications network. Most interestingly, MDC has just been upgraded by five-star Wells Fargo analyst Peter Stabler. His shift in sentiment comes with a bullish $11 price target (46% upside potential).
Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Tuesday.